他汀类与低分子肝素钙治疗急性冠脉综合征临床疗效观察

Observation of Clinical Therapeutic Effect of Statin and Heparin Calcium of Low Molecular for Acute Coronary Syndrome

目的：观察急性冠脉综合征（ACS）早期应用他汀类与低分子肝素钙治疗的临床疗效。方法：将80例ACS患者按入院顺序分为两组：2002年8月-2003年10月40例设为对照组，给予抗血小板药物，β受体阻滞剂，硝酸酯类、ACEI类治疗。2004年3月-2005年5月40例设为治疗组，在对照组基础上加用他汀类：辛伐他汀20mg，1次／d，抗凝药物：低分子肝素钙（速碧林）5000IU，皮下注射，2次／d。随访6个月，观察两组临床疗效、心电图改变、心血管事件发生情况。结果：加用他汀类与低分子肝素钙治疗ACS，临床症状有效率为87．5％，对照组为57．5％。心电图改善有效率为85％，对照组为62．5％（P〈0．05），且随诊6个月中，非致死性心梗、心力衰竭、复发性心绞痛、需再次住院治疗与需做经皮腔内冠脉成形术或冠脉旁路移植术（PTCA／CABG）病例均较对照组明显降低。结论：ACS早期给予他汀类与低分子肝素钙治疗显著提高临床疗效。

Objective： To observe the clinical therapeutic effects of statin and heparin calcium of low molecular for treating ACS. Methods：Eighty patients of ACS were divided into two groups according to the time of admission. The first 40 patients admitted from Aug,2002 to Oct, 2003 were taken as control group, given drugs of antiplatelet, Betablocker,nitrates and ACEI. The another 40 patients admitted from Mar, 2003 to May, 2005 were as treatment group, given additional Statin（Simvastatin 20mg, once a day ）and heparin calcium of low molecular （Nadroparin 5000IU, IH, bid） in addtion to above drugs of control group. After 6 months follow-up the clinicab effect, electrocardiographic changes and the sum of cardiovascular events were observed in both groups. Results： For treatment and control group the improvement of clinical symptom was 87. 5% vs 57. 5%,the improvement of ECG was 85% vs 62.5%（P〈0. 05）,the events of no-mortal myocardial infarction, recurrence of angina pectoris, readmission and performing PTCA or CABG were much less in treatment group than that in control group. Conclusion. The clinical effects were significantly improved by early using statin and heparin calcium of low molecular for treating ACS.